Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (RadCT score) in patients with chronic hepatitis B (CHB)-related cirrhosis was proposed. We validated this model for indeterminate nodules on magnetic resonance imaging (MRI). Methods: Between 2013 and 2016, Liver Imaging Reporting and Data System (LI-RADS) 2/3 nodules on MRI were detected in 99 patients with CHB. The RadCT score was calculated. Results: The median age of the 72 male and 27 female subjects was 58 years. HCC history and liver cirrhosis were found in 47 (47.5%) and 44 (44.4%) patients, respectively. The median RadCT score was 112. The patients with HCC (n=41, 41.4%) showed significantly higher RadCT scores than those without (median, 119 vs. 107; P=0.013); the Chinese university-HCC and risk estimation for HCC in CHB (REACH-B) scores were similar (both P>0.05). Arterial enhancement, T2 hyperintensity, and diffusion restriction on MRI were not significantly different in the univariate analysis (all P>0.05); only the RadCT score significantly predicted HCC (hazard ratio [HR]=1.018; P=0.007). Multivariate analysis showed HCC history was the only independent HCC predictor (HR=2.374; P=0.012). When the subjects were stratified into three risk groups based on the RadCT score (<60, 60–105, and >105), the cumulative HCC incidence was not significantly different among them (all P>0.05, log-rank test). Conclusions: HCC history, but not RadCT score, predicted CHB-related HCC development from LI-RADS 2/3 nodules. New risk models optimized for MRI-defined indeterminate nodules are required.
Abstract
Background/Aims: A risk prediction model for the development of hepatocellular carcinoma (HCC) from indeterminate nodules detected on computed tomography (CT) (RadCT score) in patients with chronic hepatitis B (CHB)-related cirrhosis was proposed. We validated this model for indeterminate nodules on magnetic resonance imaging (MRI). Methods: Between 2013 and 2016, Liver Imaging Reporting and Data System (LI-RADS) 2/3 nodules on MRI were detected in 99 patients with CHB. The RadCT score was calculated. Results: The median age of the 72 male and 27 female subjects was 58 years. HCC history and liver cirrhosis were found in 47 (47.5%) and 44 (44.4%) patients, respectively. The median RadCT score was 112. The patients with HCC (n=41, 41.4%) showed significantly higher RadCT scores than those without (median, 119 vs. 107; P=0.013); the Chinese university-HCC and risk estimation for HCC in CHB (REACH-B) scores were similar (both P>0.05). Arterial enhancement, T2 hyperintensity, and diffusion restriction on MRI were not significantly different in the univariate analysis (all P>0.05); only the RadCT score significantly predicted HCC (hazard ratio [HR]=1.018; P=0.007). Multivariate analysis showed HCC history was the only independent HCC predictor (HR=2.374; P=0.012). When the subjects were stratified into three risk groups based on the RadCT score (<60, 60–105, and >105), the cumulative HCC incidence was not significantly different among them (all P>0.05, log-rank test). Conclusions: HCC history, but not RadCT score, predicted CHB-related HCC development from LI-RADS 2/3 nodules. New risk models optimized for MRI-defined indeterminate nodules are required.
참고문헌 (30)
- El-Serag HB, "Epidemiology of viral hepatitis and hepatocellular carcinoma", Gastroenterology, 142, pp.1264~1273 (2012)
- Lee HW, "Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients", World J Gastroenterol, 22, pp.8314~8321 (2016)
- Yoon SK, "Status of hepatocellular carcinoma in South Korea", Chin Clin Oncol, 2, pp.39~ (2013)
- Pardee AD, "Immunotherapy of hepatocellular carcinoma : unique challenges and clinical opportunities", Oncoimmunology, 1, pp.48~55 (2012)
- Raza A, "Hepatocellular carcinoma review : current treatment, and evidence-based medicine", World J Gastroenterol, 20, pp.4115~4127 (2014)
- Kim BK, "Applicability of BCLC stage for prognostic stratification in comparison with other staging systems : single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma", Liver Int, 32, pp.1120~1127 (2012)
- Choi SH, "Role of surgical resection for multiple hepatocellular carcinomas", World J Gastroenterol, 19, pp.366~374 (2013)
- 서석원, "Predictors of Micrometastases in Patients with Barcelona Clinic Liver Cancer Classification B Hepatocellular Carcinoma", Yonsei Medical Journal, 58(4), pp.737~742 (2017), 연세대학교의과대학[DOI]
- Hammerstingl R, "Diagnostic efficacy of gadoxetic acid(Primovist)-enhanced MRI and spiral CT for a therapeutic strategy : comparison with intraoperative and histopathologic findings in focal liver lesions", Eur Radiol, 18, pp.457~467 (2008)
- Kim SH, "Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma", AJR Am J Roentgenol, 192, pp.1675~1681 (2009)
- Cho HJ, "Development of risk prediction model for hepatocellular carcinoma progression of indeterminate nodules in hepatitis B virus-related cirrhotic liver", Am J Gastroenterol, 112, pp.460~470 (2017)
- An C, "Liver imaging reporting and data system(LI-RADS)version 2014 : understanding and application of the diagnostic algorithm", Clin Mol Hepatol, 22, pp.296~307 (2016)
- Korean Liver Cancer Study Group and National Cancer Center, Korea, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
- European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Mitchell DG, "LI-RADS(Liver Imaging Reporting and Data System) : summary, discussion, and consensus of the LI-RADS Management Working Group and future directions", Hepatology, 61, pp.1056~1065 (2015)
- Wong GL, "Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy", World J Gastroenterol, 19, pp.6515~6522 (2013)
- Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)
- Yang HI, "Risk estimation for hepatocellular carcinoma in chronic hepatitis B(REACHB) : development and validation of a predictive score", Lancet Oncol, 12, pp.568~574 (2011)
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- Jae-Jun Shim, "Predictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis B", Gut and Liver, 10(6), pp.962~968 (2016), 거트앤리버 소화기연관학회협의회
- Sakamoto M, "Early stages of multistep hepatocarcinogenesis : adenomatous hyperplasia and early hepatocellular carcinoma", Hum Pathol, 22, pp.172~178 (1991)
- Theise ND, "Macroregenerative nodules and hepatocellular carcinoma in forty-four sequential adult liver explants with cirrhosis", Hepatology, 16, pp.949~955 (1992)
- Hytiroglou P, "Macroregenerative nodules in a series of adult cirrhotic liver explants : issues of classification and nomenclature", Hepatology, 21, pp.703~708 (1995)
- Terasaki S, "Histological features predicting malignant transformation of nonmalignant hepatocellular nodules : a prospective study", Gastroenterology, 115, pp.1216~1222 (1998)
- Seki S, "Outcomes of dysplastic nodules in human cirrhotic liver : a clinicopathological study", Clin Cancer Res, 6, pp.3469~3473 (2000)
- Borzio M, "Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development", J Hepatol, 39, pp.208~214 (2003)
- Kobayashi M, "Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis", Cancer, 106, pp.636~647 (2006)
- Seeff LB, "Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial", Clin Gastroenterol Hepatol, 8, pp.877~883 (2010)
- Colecchia A, "Prognostic factors for hepatocellular carcinoma recurrence", World J Gastroenterol, 20, pp.5935~5950 (2014)
- Khalili K, "Indeterminate 1-2-cm nodules found on hepatocellular carcinoma surveillance : biopsy for all, some, or none", Hepatology, 54, pp.2048~2054 (2011)